V. Andreotti

发表

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

V. Poroikov, A. Okorokov, V. Grinkevich, 2018 .

A clinically applicable method to preserve urine and bladder washing cells for flow cytometric monitoring of bladder cancer patients.

L. Howell, R. deVere White, A. Deitch, 1990, The Journal of urology.

Fixation method useful for cytologic examination and DNA flow cytometry of exfoliated bladder cells.

L. Howell, A. Deitch, V. Andreotti, 1993, Urology.

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

P. Ascierto, V. de Giorgi, S. Manoukian, 2016, Journal of the American Academy of Dermatology.

Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1

A. Ballestrero, A. Goldstein, S. Manoukian, 2020, Cancers.

MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients

P. Queirolo, V. Andreotti, M. Barile, 2012, Experimental dermatology.

The 5′-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding

R. Spitale, A. Inga, A. Bisio, 2015, Oncotarget.

Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent.

A. Inga, P. Monti, G. Fronza, 2008, DNA repair.

Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients

V. Andreotti, S. Sciallero, P. Ghiorzo, 2022, Cancers.

A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer

Federica Grillo, Michele Minuto, Paola Ghiorzo, 2016, Endocrine.

Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup

A. Ballestrero, I. Stanganelli, P. Queirolo, 2022, ESMO open.

CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients

A. Ballestrero, P. Queirolo, V. Andreotti, 2019, Journal of the American Academy of Dermatology.

Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma

D. Massi, V. Andreotti, G. Zoppoli, 2022, International journal of molecular sciences.

Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)

I. Stanganelli, P. Queirolo, M. Mandalà, 2020, Diagnostic Pathology.

Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.

A. Inga, G. Fronza, Y. Ciribilli, 2007, Mutagenesis.

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications

V. Andreotti, P. Ghiorzo, L. Pastorino, 2020, Frontiers in Molecular Biosciences.

Species identification and confirmation of human and animal cell lines: a PCR-based method.

Barbara Parodi, Ottavia Aresu, Tiziana Ruzzon, 2002, BioTechniques.

Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.

H. Hakonarson, K. Brown, M. Iles, 2019, Carcinogenesis.

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

V. Andreotti, P. Ghiorzo, W. Bruno, 2020, Frontiers in Molecular Biosciences.

Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148

Geoffrey S. Tobias, K. Nielsen, J. Malvehy, 2017, Nature Communications.

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide

Ivana K. Kim, S. Puig, N. Hayward, 2018, Journal of the National Cancer Institute.

Current State of Target Treatment in BRAF Mutated Melanoma

V. Andreotti, P. Ghiorzo, W. Bruno, 2020, Frontiers in Molecular Biosciences.

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

V. Grinkevich, G. Selivanova, A. Inga, 2021, bioRxiv.

The Coordinated P53 and Estrogen Receptor Cis-Regulation at an FLT1 Promoter SNP Is Specific to Genotoxic Stress and Estrogenic Compound

D. Menendez, A. Inga, Y. Ciribilli, 2010, PloS one.

Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history

P. Queirolo, V. Andreotti, M. Tibiletti, 2013, Pigment cell & melanoma research.

Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients

C. Massone, M. Pizzichetta, P. Queirolo, 2020, Journal of Translational Medicine.

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations

A. Ballestrero, P. Queirolo, M. Gualco, 2017, OncoTarget.

Functional analysis of a CDKN2A 5’UTR germline variant associated with pancreatic cancer development

A. Inga, A. Bisio, V. Andreotti, 2017, PloS one.

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry

A. Ballestrero, P. Queirolo, M. Gualco, 2016, Oncotarget.

The CDKN2A/p16INK4a 5′UTR sequence and translational regulation: impact of novel variants predisposing to melanoma

P. Queirolo, R. Spitale, A. Inga, 2016, Pigment cell & melanoma research.

Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting

P. Queirolo, V. Andreotti, G. Zoppoli, 2023, International journal of molecular sciences.

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia

S. Puig, D. Elder, N. Hayward, 2021, Genetics in Medicine.

p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System

J. Jordan, A. Inga, P. Monti, 2011, PloS one.

Case Report: A BRCA2 Mutation Identified Through Next-Generation Sequencing in a Birt–Hogg–Dubè Syndrome Family

G. Martinelli, D. Calistri, V. Andreotti, 2022, Frontiers in Oncology.

Accelerated repair and reduced mutagenicity of oxidative DNA damage in human bladder cells expressing the E. coli FPG protein

P. Degan, S. Zupo, V. Andreotti, 2006, International Journal of Cancer.

Molecular Assessment in Patients with Melanoma: When and Why?

V. Andreotti, P. Ghiorzo, L. Pastorino, 2020 .

Understanding the complex crosstalk between p53 and the estrogen receptors at a polymorphic variant of the VEGF receptor Flt-1 promoter

D. Menendez, A. Inga, Y. Ciribilli, 2008 .

The 5′-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding

R. Spitale, A. Inga, V. Andreotti, 2015, Oncotarget.

Germline POT1 Variants: A Critical Perspective on POT1 Tumor Predisposition Syndrome

V. Andreotti, P. Ghiorzo, L. Pastorino, 2024, Genes.